Akebia Therapeutics (AX9) Stock Price & Analysis
AX9 Stock Chart & Stats
- Day’s Range
- EUR 0.65 - EUR 0.65
- 52-Week Range
- EUR 0.49 - EUR 1.90
- Previous Close
- EUR 0.67
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 174.71M
- Enterprise Value
- EUR 360.90M
- Total Cash (Recent Filing)
- EUR 155.55M
- Total Debt (Recent Filing)
- EUR 53.96M
- Price to Earnings (P/E)
- ―
- Beta
- 1.09
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- -0.03
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross Margin
A gross margin near 79% indicates favorable product-level economics and leaves meaningful capacity to support commercial investment. This provides a stronger foundation for future operating leverage, although the benefit depends on Akebia converting gross profit into sustainable operating profitability.
Improved Cash Generation
The shift to positive operating and free cash flow is a meaningful improvement in financial durability because it demonstrates recent cash generation alongside accounting losses. If maintained, this could reduce reliance on external capital and provide greater flexibility to fund ongoing commercial and pipeline activities.
Commercial Product And Pipeline
Akebia has an established commercial product rather than relying solely on preclinical or development-stage assets, while its renal and cardiometabolic pipeline offers additional avenues for growth. This combination can support business continuity and broaden future revenue opportunities if programs progress.
Bears Say
Persistent Operating Losses
The return to negative EBIT and EBITDA, combined with a recent revenue decline, shows that improved gross profitability has not yet translated into consistent earnings power. Continued operating losses can constrain reinvestment and make future financial performance more dependent on successful revenue stabilization.
Fragile Balance Sheet
Debt exceeding equity and the history of negative equity indicate limited balance-sheet resilience relative to the company’s uneven profitability. Although leverage improved from 2025, financial flexibility remains sensitive to weaker operations, making capital allocation and funding decisions more consequential.
Nasdaq Listing Compliance Risk
The Nasdaq deficiency creates a material corporate and financing overhang because failure to regain compliance could lead to delisting or require a reverse stock split. The extended compliance window provides time to respond, but the outcome remains uncertain and could disrupt market access.
Akebia Therapeutics News
Akebia’s Vadadustat Trial Nears Data Readout, Raising Stakes in Dialysis Anemia Market
Akebia Therapeutics ($AKBA) announced an update on their ongoing clinical study. Akebia Therapeutics is running a Phase 3 study called “A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three
AX9 FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
What is Akebia Therapeutics’s market cap?
When is Akebia Therapeutics’s upcoming earnings report date?
How were Akebia Therapeutics’s earnings last quarter?
Is Akebia Therapeutics overvalued?
Does Akebia Therapeutics pay dividends?
What is Akebia Therapeutics’s EPS estimate?
How many shares outstanding does Akebia Therapeutics have?
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Akebia Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Akebia Therapeutics Stock Smart Score
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Butler
- Employees
- 194
- Website
- www.akebia.com
- Address
- 180 Third Avenue, Waltham, MA, 02451, US
Akebia Therapeutics (AX9) Earnings & Revenues
AX9 Earnings Call
Earnings Call SentimentNeutral
The call highlights strong commercial momentum for Vafseo (32% revenue growth, ~60% patient growth quarter-over-quarter, higher prescriber engagement and improved adherence under observed dosing) and meaningful pipeline progress with supportive clinical data and upcoming readouts. However, legacy product Auryxia faces notable generic-driven revenue decline (≈-17%), the company swung to a net loss in the quarter, experienced sizable inventory write-downs and higher operating expenses, and cash declined q/q. While the launch and clinical developments are encouraging and provide a clear growth narrative, the near-term financial headwinds and competitive/enrollment risks temper the outlook.
View all DE:AX9 earnings summariesAX9 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 5 | 9 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 6 | 0 | 6 |